About Elysium Therapeutics
Our Vision
Elysium’s vision is to drive necessary change in the opioid industry by creating viable safety features that reduce Opioid Use Disorder, save lives, and effectively treat pain.
Join us as we create a safer, more pain-free world.
Company Strengths
-
Compelling in vivo and human proof-of-concept for New Chemical Entities (NCEs) comprised of FDA-approved drugs
Intelligently designed SMART™ NCEs provide early human proof of concept
Likely to receive Breakthrough Technology Designation with hPOC
Former Division Director of FDA on Elysium’s board and believes that generic opioids could be forced off the market
-
Will continue to leverage non-dilutive grant funding
Awarded $16M to date
Funding supported by NIH and Ohio Third Frontier
Virtually run company, resulting in lower burn rate
-
Multiple solutions to address key underlying issues that drive the opioid crisis
Broad applicability could yield multiple products within 3-5 years
-
O2P solution focused on acute pain management, which is 90% of the total opioid market
150 countries currently restrict opioids because of existing dangers that our solutions address
Addressable markets (acute pain, OUD and overdose rescue) are billion to multi-billion dollar markets
-
Elysium has strongest type of IP in our industry, “Novel Compositions of Matter”
Issued patents in the US and internationally
Interested in partnering with Elysium Therapeutics?
Join us in our quest to reduce suffering from pain, Opioid Use Disorder, and fatal opioid overdose. We have the innovation, but we need partners who share our passion, have funds to support our mission, and may have the political muscle to help push our life-saving solutions forward.